The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergy
Rozanne Arulanandam(Ottawa Hospital), Jean‐Simon Diallo(University of Ottawa)
Cited by 16
Related Papers
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapy
|Molecular Therapy|2023|23